Selexys Pharmaceuticals Signs CMO Agreement with Cytovance Biologics

Published on: 

Cytovance Biologics and Selexys Pharmaceuticals enter an agreement for development of clinical trial materials.

Cytovance Biologics, a CMO of mammalian and microbial biologics, announced a development and manufacturing agreement for SELK2 with Selexys Pharmaceuticals, an Oklahoma City-based clinical stage biopharmaceutical company.

SELK2 is an investigational humanized monoclonal antibody directed toward the treatment of Crohn’s disease and multiple myeloma. Selexys has contracted Cytovance Biologics as its CMO to provide process development, scale up, and cGMP manufacturing services of SELK2 in support of a Phase I human clinical trial.


Source: Cytovance Biologics